Protein product labeling

TES-32 is the most abundant single protein product secreted by the parasite. It is also heavily labelled by surface iodination of live larvae (Maizels et al., 1984, 1987), and is known by monoclonal antibody reactivity to be expressed in the cuticular matrix of the larval parasite (Page et al, 1992a). TES-32 was cloned by matching peptide sequence derived from gel-purified protein to an expressed sequence tag (EST) dataset of randomly selected clones from a larval cDNA library (Loukas et al., 1999). Because of the high level of expression of TES-32 mRNA, clones encoding this protein were repeatedly sequenced and deposited in the dataset (Tetteh et al., 1999). Full sequence determination showed a major domain with similarity to mammalian C-type (calcium-dependent) lectins (C-TLs), together with shorter N-terminal tracts rich in cysteine and threonine residues. Native TES-32 was then shown to bind to immobilized monosaccharides in a calcium-dependent manner (Loukas et al., 1999). 

If specific amino acid-type labeling is required, the labeled amino acid is added to the fermentation of the expression host (topic 1 above, see Sect. 1.2.3). In this case, a thorough isotope analysis of the expressed protein is advisable prior to NMR spectroscopic investigations. This is preferentially achieved by GC-MS analyses of the hydrolyzed amino acids from the protein product. 

Pharmacokinetics According to the product label, the pharmacokinetics of eptihbatide are linear and dose proportional. Plasma elimination half-life is approximately 2.5 hours. The extent of eptihbatide binding to human plasma protein is about 25% its mean volume of distribution is 185mPkg. Clearance in patients with coronary artery disease is 55-58 ml/kg per hour. Clinical studies have included 2418 patients with serum creatinine between 1.0 and 2.0mg/dl without dose adjustment. No data are available in patients with more severe degrees of renal impairment, but plasma eptihbatide levels are expected to be higher in such patients. Patients in clinical studies were older than the subjects in clinical pharmacology studies, and they had lower total body eptihbatide clearance and higher eptihbatide plasma levels. Men and women showed no important differences in the pharmacokinetics of eptihbatide. 

Possibly the most important, and least understood, aspect of spray-dried flavorings manufacture is the role the wall material plays in this process. The polymers utilized for this product are controlled by FDA constraints, cost, finished product labelling considerations and compatability, functionality and historical usage. Given these considerations, polymers selected for the retention and maintenance of labile flavors and aromas in industrial spray dried, food grade systems include both carbohydrate (hydrolyzed starches, "lipophilic starches, plant exudates) and protein. The importance of these wall materials should not be underestimated. 

Figure 8.5 Pomegranate by-product (PBP) consumption by E° mice attenuates atherosclerotic lesion development, in association with reduction in macrophage oxidative stress and Ox-LDL uptake. E° mice consumed PBP (17 or 51.5 mg gallic acid equivalents/kilogram/day) for 3 months. Control mice received only water (placebo). At the end of the study, the mice aortas as well as the mice peritoneal macrophages were harvested. (A) Atherosclerotic lesion size determination. (B) Total macrophage peroxide levels were determined by the DCFH-DH assay. (C) For determination of macrophage paraoxonase 2 (PON2) lactonase activity, cells (2 x 10e) were incubated with 1 mmol/L dihydrocoumarin in Tris buffer, and the hydrolysis rate was determined after 10 min of incubation at 25°C. (D) The extent of Ox-LDL (25 pg of protein/ milliliter, labeled with FITC) uptake by the mice macrophages (1 x 10e) was determined by flow cytometry. Results are expressed as mean S.D. of three different determinations. = p < 0.01 versus placebo.

The detection of trace levels of residual DNA in protein products is a formidable challenge, primarily due to the extremely low detection limits required (e.g., 10-100 pg/dose). Probe hybridization, using a radiolabeled DNA probe derived from host cell DNA, has been in the method most commonly used, due to the extraordinary sensitivity of the assay. However, it is important to remember that this assay will recognize only DNA complementary to the labeled probe (i.e., other forms of DNA will not be recognized in the assay). Several techniques are now available for general detection of DNA at relatively low levels, and these methods are expected to come into more widespread use in the future. One such method is based on the use of DNA binding proteins in a format similar to an ELISA assay. 

From a strict biochemical point of view a clear-cut definition of the role of the liver in the biosynthesis of any particular plasma protein can be made only when the particular protein has been clearly and cleanly isolated, as in the case of fibrinogen. The practical difficulties of effecting such isolations on a small scale from isotopic labeling studies of the plasma proteins, such as we have described, seriously militate against such a detailed demonstration at present. The use of fractionation techniques with greater resolving power such as acrylamide gel electrophoresis already show some promise in our laboratory toward affording a more definitive picture of the biosynthetic role of the liver and the nonhepatic tissues in plasma protein production. 

Micellar electrochromatography was applied by Ramsey s group on a two-dimensional separation system with a microfabricated device, using two different separation mechanisms, electrochromatography as the first dimension and capillary electrophoresis as the second dimension [39]. For detection of proteins, fluorescently labeled products from tryptic digests of (3-casein were analyzed in 13 min with this system [39],... 

In the case of FBDD, structural enablement means having either suitable crystals for X-ray or a suitably isotopi-cally labeled protein sample for NMR. Obtaining suitable crystals for X-ray can take anywhere from 4 (literature precedent) to 18 (novel) months. These times presume that protein production must be developed in-house. In cases where high-quality proteins can be readily purchased, we have seen on rare occasions this time to structural enablement cut down to approximately 2 months. 

---